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Abstract
The objective of this study was to evaluate current approaches to economic modeling in
rheumatoid arthritis (RA) and propose a new conceptual model for evaluation of the cost-
effectiveness of RA interventions. We followed recommendations from the International
Society of Pharmacoeconomics and Outcomes Research-Society of Medical Decision Mak-
ing (ISPOR-SMDM) Modeling Good Research Practices Task Force-2. The process
involved scoping the decision problem by a working group and drafting a preliminary cost-
effectiveness model framework. A systematic literature review (SLR) of existing decision-
analytic models was performed and analysis of an RA registry was conducted to inform the
structure of the draft conceptual model. Finally, an expert panel was convened to seek input
on the draft conceptual model. The proposed conceptual model consists of three separate
modules: 1) patient characteristic module, 2) treatment module, and 3) outcome module.
Consistent with the scope, the conceptual model proposed six changes to current economic
models in RA. These changes proposed are to: 1) use composite measures of disease
activity to evaluate treatment response as well as disease progression (at least two mea-
sures should be considered, one as the base case and one as a sensitivity analysis); 2) con-
duct utility mapping based on disease activity measures; 3) incorporate subgroups based
on guideline-recommended prognostic factors; 4) integrate realistic treatment patterns
based on clinical practice/registry datasets; 5) assimilate outcomes that are not joint related
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(extra-articular outcomes); and 6) assess mortality based on disease activity. We proposed
a conceptual model that incorporates the current understanding of clinical and real-world
evidence in RA, as well as of existing modeling assumptions. The proposed model frame-
work was reviewed with experts and could serve as a foundation for developing future cost-
effectiveness models in RA.
Introduction
Rheumatoid arthritis (RA) is a progressive disease characterized by inflammation of synovial
tissue with symmetric involvement of peripheral joints of the hand, feet, and wrists[1,2]. The
prevalence of RA ranges from 0.4% to 1.3% [3]. RA not only contributes to reduced survival,
health related quality of life (HRQOL), activities of daily living and work productivity, but is
also associated with higher health resource utilization and costs compared to general popula-
tion and osteoarthritis patients [4–7]. Most RA-related direct costs are associated with biologic
disease modifying anti-rheumatic drugs (bDMARDs), which have improved outcomes in RA
patients [8–11]. Since the introduction of these agents, our knowledge of RA as a disease has
greatly increased and new therapies as well as combination therapies (of different bDMARDs
or of bDMARDs in combination with synthetic (sc)DMARDs) targeting multiple immune
pathways are being developed [12,13]. The development of novel interventions is accompanied
by the introduction of bioequivalents or biosimilars of existing bDMARDs. In an environment
featuring multiple therapeutic options to manage RA patients on one side and constrained
health resources on the other, cost-effectiveness models that enable more precise estimations
of cost and benefits could reduce the risk of inefficient resource allocation.
The framework for cost-effectiveness models for treatments in RA has evolved since first
published in early 2000s, with the introduction of bDMARDs [14,15]. The current modeling
approach has served to establish economic benefits of bDMARDs in most countries, in moder-
ate to severe RA patients with inadequately respond to methotrexate [16,17]. In our opinion
previously, published models have potential room for improvement in six areas. First, current
models base treatment response on composite measures of disease activity such as European
League Against Rheumatism (EULAR) response [18], American College of Rheumatology
(ACR) response [19], and Disease Activity Scores in 28 joints C-reactive protein (DAS28-CRP)
[20]. These disease activity measures are not aligned to guideline-recommended target mea-
sures of remission and hence cannot evaluate the cost-effectiveness of policies designed to
implement treatment guideline-based targets [21,22]. In addition, these measures are biased
(favorably) to certain therapeutic interventions that disproportionately impact individual com-
ponents of the composite measure for example CRP with interleukin-6 (IL-6) inhibitors; this is
discussed further in results section under new conceptual model [23].
Second, disease progression in these models is based on physical functioning measured by
the Health Assessment Questionnaire (HAQ) [24]. HAQ changes are related to inflammatory
disease activity in early RA and predominately to structural damage in longstanding RA. Thus
more rapid decline in HAQ on treatment is observed in patients with RA of recent onset, com-
pared to those with established RA [25]. The greater reduction in HAQ observed with treat-
ments in patients with early versus established RA highlights the ceiling effect of HAQ and
thus may be insensitive to beneficial treatment effects.
Third, contemporary models derive utility scores from the HAQ, based on mapping algo-
rithms. Nonlinear models are now recommended, and overall mapping of HAQ to European
Conceptual model for cost effectiveness analysis in RA
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Quality of life 5 dimension (EQ-5D) [26] has been improved by including disease activity and
pain in these models [27,28]. However, no study (to our knowledge) has evaluated the impact
of other dimensions of RA or of different composite measures on utility scores.
Fourth, certain baseline characteristics, such as age, gender, and HAQ score, are accounted
for in current models. However, most of these models do not report incremental cost-
effectiveness ratios (ICERs) according to important subgroups. Recent studies have evaluated
ICER within a limited number of RA subgroups [29,30].
Fifth, current modeling approaches focus on joint-related outcomes in RA, largely at the
expense of extra-articular manifestations. Extra-articular manifestations occur in 18% to 41%
of patients with RA [31–35]. A growing body of evidence—mainly derived from observational
databases and registries—suggests that specific RA therapies, including methotrexate and
bDMARDs, may reduce the risk of extra-articular cardiovascular disease [CVD] manifesta-
tions with RA [36,37].
Sixth and finally, long-term treatment discontinuation in current models is based on real-
world registry data, and these models allow for patients to cycle through tumor necrosis factor
inhibitor (TNF-i) via limited sequential use of bDMARDs [28,38]. However, these same mod-
els do not allow for data in which health providers escalate doses or re-initiate bDMARDs
once treatment has been discontinued or stopped if the patient experiences a flare [39]. These
factors may result in underestimating both increasing therapeutic benefits and costs. Although
contemporary RA therapy is moving toward lowering the dose of the bDMARDs in patients
once they have attained a predefined target disease activity state, such dose de-escalation is not
incorporated in previously reported models [40–43].
Taken together, these factors point to unmet needs related to pharmacoeconomic modeling
in RA. Consideration of these aspects in future economic modeling of RA treatments could
enable evaluation of costs and benefits of therapies in manner that reflects prevailing clinical
realities with the aim of producing more accurate cost-effectiveness estimates. The objective of
this analysis was to review current economic models in RA and propose a revised conceptual
model framework.
Methods
In developing the conceptual model, the recommendations outlined by the International Soci-
ety of Pharamacoeconomic and Outcomes Research-Society of Medical Decision Making
(ISPOR-SMDM) Modeling Good Research Practices Task Force-2 were followed [44]. As
depicted in Fig 1, the process involved scoping out the decision problem by a working group
and drafting a preliminary cost effectiveness model framework. A systematic literature review
(SLR) of existing decision-analytic models was performed and analysis of a RA registry was
conducted to inform the structure of the draft conceptual model. Finally, an expert panel was
convened to seek input on the draft conceptual model.
Scoping
The knowledge gaps in current models as explained in the introduction were elucidated in a
three-member (EA, MA, MR) working group. The working group focused on various aspects
of the model, such as 1) measures to access treatment responses/treatment targets, 2) measure
to assess RA disease progression, 3) utility mapping, 4) RA subgroups, 5) treatment patterns
(e.g. dose escalation, dose de-escalation) 6) extra-articular outcomes, and mortality. Based on
these aspects the working group put together a list of revisions of existing models (S1 Appen-
dix) and drafted a conceptual model (S2 Appendix). The draft conceptual model was based on
the working group analyses of a RA registry to explore treatment targets and extra-articular
Conceptual model for cost effectiveness analysis in RA
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manifestation of RA, and RA subgroups, which have been published elsewhere [45–48]. In
addition, the working group relied on literature and knowledge of clinical guidelines to inform
model development.
SLR
A review of existing decision-analytic models on the cost-effectiveness of RA therapies pub-
lished in English since 2006 was conducted as part of the scoping process. The search strategy
is depicted in S3 Appendix. Primary searches were conducted in Medline, EMBASE, and
EconLit simultaneously using Ovid based on the search strategy outlined. In addition to the
SLR, recent publication on methodologies of economic modeling in RA was also reviewed
[49]. To supplement the database search, a manual search of previous health technology assess-
ment (HTA) reports was conducted on the UK National Institute for Health and Clinical
Excellence website (https://www.nice.org.uk/guidance/ta375/history [last accessed Nov 2017]).
The primary objective of the SLR was to identify published economic evaluations of
Fig 1. Schematic overview of the development process of the conceptual model.
https://doi.org/10.1371/journal.pone.0205013.g001
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bDMARDs in RA. The SLR focused on model structure, short-term treatment targets/
responses, RA disease progression (long-term response when initial treatment is successful),
utility mapping, patient subgroups (with characteristics that could be treatment effect modifi-
ers), treatment aspects (switching, dose escalation, de-escalation), time horizon, and mortality
associated with RA.
Analysis to inform conceptual model
To inform disease progression and utility mapping in the conceptual model, the working
group conducted a retrospective analysis of a RA registry. A longitudinal sequential registry of
primarily established RA patients was used for this analysis. In this registry, disease activity
was measured annually during rheumatology visits using multiple composite functional mea-
sures [50]. These included the DAS28-CRP, Simplified Disease Activity Index (SDAI) and
Clinical Disease Activity Index (CDAI) [51]. The generic HRQOL index EQ-5D was evaluated
every 6 months via both mailed questionnaires and in-person interview (during annual visit).
The progression of RA using various composite measures as well as changes in these disease
activity over time was evaluated using general linear models. Mapping algorithms based on
DAS28-CRP, SDAI, and CDAI were compared to the physical functioning (HAQ)-based map-
ping algorithm. Fixed-effects models were used to estimate the best predictors of EQ-5D,
because within-patient variability over time is more important than between patient variability
in economic models [52].
Expert panel
An expert panel comprising two rheumatologist (AB, MW), one health economist (MS), and
two epidemiologists/health services researchers (KM, SV) was convened to provide input to
the conceptual model. The draft conceptual model was presented to each expert in a multistep
approach. In the first step, a member of the working group (EA) shared the discussion guide
developed by the working group with the expert panel members. The discussion guide con-
tained an overview and limitations of current modeling approaches in RA as well as the pro-
posed conceptual model structure. It also included a brief questionnaire that focused on the
proposed modifications to the cost-effectiveness model. In the second step, opinions from all
experts of the panel were gathered via individual interviews. The third step involved updating
the draft conceptual model and collating all responses to questions and comments. The revised
document was shared with all experts for additional inputs. Additional updates were then
incorporated, and the conceptual model was sent back to the panel for a final opportunity to
provide suggestions.
Results
Scoping
The decision problem that the conceptual model would address was defined as identifying
cost-effective drug interventions for moderate-to-severe RA that result in the most health ben-
efits for the overall RA population as well as for specific subgroups (such as those with poor
prognostic factors). This includes current and novel interventions that are being developed
and may be introduced in clinical practice in the future as monotherapy or combination
therapies.
Conceptual model for cost effectiveness analysis in RA
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SLR
A total of 32 economic evaluation studies were identified by the initial SLR, 5 of which were
review articles. The remaining 27 manuscripts evaluated are summarized in S3 Appendix
Table 3 [29,38,49–77]. The primary model structures were cohort based or individual patient
simulations, which included discrete event simulations and individual patient Markov models.
More recent published models tended to be primarily individual patient simulations.
The assumed relationship between different model variables is summarized in the influence
diagram represented in Fig 2. Each solid arrow represents a direct effect of one variable on the
other, while the dashed lines represent the mathematically derived structural relationships. In
general, these models evaluate short-term (3 to 6 months) treatment effects based on clinical
trial efficacy. Based on the short-term efficacy and probability of adverse events (AEs), a deci-
sion rule was included in the model for a patient to continue treatment or not. If treatment is
continued, then disease progression is estimated based on HAQ change over time. In recent
models HAQ change over time is based on mixture models, while earlier models used linear
progression (0 per annum for bDMARDs and 0.03 to 0.045 per annum for cDMARDs)
[29,64]. HAQ scores are then mapped to HRQOL, mortality rates and resource use, using
mapping algorithms. The long-term treatment duration in the majority of the simulation
models is based on real-world registry data, extrapolated using survival models with time to
treatment discontinuation as outcomes. The endpoint driving cost-effectiveness models in RA
is primarily physical functioning, whereas other endpoints such as radiographic progression
are rarely used [76].
New conceptual model
The conceptual model drafted by the working group is represented in Fig 3. The proposed
conceptual model is an individual patient simulation model with a lifetime horizon proposed
to capture short-term and long-term benefits and cost of interventions. Outcomes are defined
as quality-adjusted life years (QALYs) and life-years gained (LYG). This model is intended for
HTA and is based on the payer’s perspective and has three distinct modules: 1) patient
Fig 2. RA economic model influence diagram for structural relationship.
https://doi.org/10.1371/journal.pone.0205013.g002
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characteristic module, 2) treatment module and 3) outcome module. This framework enables
addressing issues of treatment responses, RA subgroups, real world treatment patterns and
extra-articular manifestation of RA mentioned in the introduction. This proposed conceptual
model should be seen as “aspirational” because not all data elements required to populate the
model are available (at the time of writing) but are likely to become available in the future. The
ISPOR-SMDM Modeling Good Research Practices Task Force-2 stresses that conceptual mod-
els should not be driven solely by the presence or absence of clinical data [44].
To improve the clinical relevance of the economic models in RA, it is important to align
treatment responses to guideline-recommended targets, which are based on composite mea-
sures of disease activity [21,22]. The working group proposed the expert panel to consider
CDAI as a measure of treatment response in the conceptual model (change 1a). This was pri-
marily based on observed associations between treatment targets and outcomes of physical
functioning (HAQ), HRQOL (i.e. EQ-5D), and health resource use. A greater improvement
was observed in these outcomes among patients attaining (vs. not attaining) a CDAI based tar-
get, compared to SDAI and DAS28-CRP based targets [47]. In addition, CDAI has acceptable
psychometric properties, including validity and sensitivity to change [78–81]. CDAI remission
does not include levels of CRP or erythrocyte sedimentation rate (ESR) which are primarily
impacted by therapies such as IL-6 and janus kinase inhibitors. Thus, the new conceptual
model could include a CDAI score of <2.8 (remission) or10 (LDA) as a definition for
responder for treatment continuation. In terms of disease progression, the working group pro-
posed CDAI change over time (change 1b). This was based on analysis of changes in CDAI,
SDAI and DAS28-CRP in a cohort of patients with mostly established RA [50]. Results of these
analyses indicate that response to change over time is dependent on disease duration and mea-
surement of disease activity under consideration (S4 Appendix).
Finally, the mapping exercise of disease activity measures and physical functioning to EQ-
5D indicates that mapping models predicated on CDAI and Routine Assessment of Patient
Index Data-3 (RAPID-3) measures have the best fit according to r2 and root mean square
error values (Table 1). RAPID-3 is an index of physical function, patient pain, and patient
Fig 3. Draft conceptual model to evaluate cost effectiveness in RA.
https://doi.org/10.1371/journal.pone.0205013.g003
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global, and as such a PRO index of disease activity (or impact). Based on these findings, the
working group proposed to the expert panel that the conceptual framework should include
utilities based on disease activity measure (CDAI) and RAPID-3 (change 2).
Based on current evidence, the conceptual model accommodates subgroups with a high
risk of disease progression such as those with multiple prognostic factors (change 3). Addi-
tional subgroups that the working group considered important for inclusion were patients
with susceptible to infections. The patient characteristic module accounts for patient character-
istics when entering the model and at subsequent time points. This module enables risk strati-
fication of RA patients based on prognostic factors. Some commonly reported prognostic
factors for a more rapid and aggressive disease are double seropositivity for anti-cyclic citrulli-
nated peptide antibody (ACPA) and rheumatoid factor (RF), as well as erosions, disease activ-
ity and measures of inflammation (CRP/ESR) [81–85]. There is evidence that certain
prognostic factors can be considered as treatment effect modifiers [86–88]. Subgroups based
on patients’ risks of infections were considered, RA patients with high disease activity also
have increased risk of infections as well as CVD [89,90]. In addition, evidence indicates that
glucocorticoids and certain DMARDs increase the risk of infection in RA patients [91,92] and
because prevalent RA patients tend to be elderly and thus at increased risk for infections.
The treatment module accommodates all treatment changes (change 4), in patients who do
not attain remission or low disease activity (LDA) or patients who experience AEs within 3 to
6 months (or secondary failure) after treatment initiation. In addition, the proposed concep-
tual model allows for flexibility in dose escalation. Data from observational studies have shown
Table 1. Fixed effects regression models for EQ5D.
Models R-Square Root MSE F- value
Patient global, Patient pain scale RADAI Joint Score 0.70 0.09 14.2
RAPID3, RADAI Joint Score 0.72 0.09 14.3
RAPID3 0.71 0.09 13.8
RAPID3, CDAI 0.75 0.09 7.4
mHAQ 0.68 0.10 15.4
mHAQ, RADAI Joint Score 0.70 0.09 16.7
mHAQ, CDAI 0.71 0.09 7.8
mHAQ, mHAQ square 0.68 0.10 15.4
mHAQ, pain 0.70 0.09 14.4
mdHAQ, RADAI Joint Score 0.70 0.09 17.0
mdHAQ 0.68 0.10 15.8
Models with baseline co-variates of age, duration, CRP and serostatus
Patient global, Patient pain scale RADAI Joint Score 0.74 0.09 7.5
RAPID3, RADAI Joint Score 0.73 0.09 15.1
RAPID3 0.71 0.09 14.0
RAPID3, CDAI 0.75 0.09 7.4
mHAQ 0.68 0.10 15.4
mHAQ, RADAI Joint Score 0.69 0.09 16.7
mHAQ, CDAI 0.71 0.09 7.8
mHAQ, mHAQ square 0.68 0.10 15.4
mHAQ, pain 0.70 0.09 14.5
mdHAQ, RADAI Joint Score 0.70 0.09 14.6
mdHAQ 0.68 0.10 15.7
https://doi.org/10.1371/journal.pone.0205013.t001
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that some patients require upward dose adjustments, reduced dose interval for bDMARDS, or
addition of glucocorticoids and/or nonsteroidal anti-inflammatory drugs (glucocorticoids/
NSAIDs) to some bDMARDs in order to achieve or maintain a clinical response [93,94].
Upward dose adjustments are associated with increased medication costs and potentially
adverse reactions. Dose escalation is not in the summary of the product characteristics of any
of the current approved DMARDs.
The outcome module incorporates disease progression and its impact on both joint and
extra-articular outcomes. The conceptual model accommodates extra-articular disease out-
comes, principally CVD events (change 5). These events were considered by the working
group primarily based on available epidemiologic data, as well as on the treatment effects and
the cost implications of these outcomes. The working group proposed incorporation of RA-
specific mortality risk based on disease activity in the economic model once more data
becomes available (change 6).
Expert panel
Members of the expert panel debated the draft model structure, challenging the level of evi-
dence to support several proposed changes. Nevertheless, a majority of the panel agreed that
the model should enable subgroup analysis by prognostic factors, and also investigate the need
to accommodate increased risk of infection (change 3). The experts agreed on QALYs should
be the main outcome and, mortality based on RA disease activity (change 6). In addition, there
was agreement on further exploring the impact of including extra-articular manifestations on
ICERs (change 5).
The expert panel also acknowledged the advantage of having a disease activity measure for
both treatment response and disease progression (change 1). Questions were raised on CDAI
data availability from historic phase 3 programs and concerns were mentioned about the sub-
jective elements of CDAI, such as estimation of tender joint counts, patient and physician
global health, which are unweighted and can make the measure less reliable. At the same time,
the members of the expert panel acknowledged that this perceived limitation might also apply
to other currently available composite measures. The least agreement among experts was on
the proposed mapping of only disease activity (change 2) to HRQOL utilities (i.e. EQ-5D).
Recommendation was to explore the use of mixed logit models, based on disease activity and
HAQ with other dimensions of RA such as pain, fatigue. Strengths and limitations of the rec-
ommended changes, along with expert inputs and level of agreement among experts concern-
ing the proposed changes, are summarized in Table 2.
After expert panel inputs had been incorporated, the draft conceptual model was further
modified and these further changes are reflected in the updated conceptual model (Fig 4).
Because there is no clinical criterion or reference standard disease activity measure, the con-
ceptual framework was revised to incorporate at least two disease activity measures: one as a
“base case” and the other for sensitivity analyses concerning treatment effect as well as disease
progression (change 1). For example CDAI or SDAI or other disease activity measures could
be used as the base case and DAS28-CRP for a sensitivity analysis. The updated conceptual
model also includes, in the same framework, patients who have not been exposed to
csDMARDs or who have not responded adequately to them. According to input from the
expert panel, the conceptual model included treatment intensification (glucocorticoids and/or
NSAIDs) before the patient received bDMARD switch and also dose de-escalation in patients
attaining remission (change 4). The final update based on expert input was the inclusion of
pulmonary extra-articular manifestation in addition to CV extra-articular effects of RA
(change 5).
Conceptual model for cost effectiveness analysis in RA
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Discussion
This study used a well-established methodology to propose a conceptual framework for devel-
oping future models in RA to evaluate the cost effectiveness of therapies [44]. The current cost
effectiveness modeling framework in RA was introduced with the advent of TNF-i. Since then
our knowledge of RA disease mechanism, impact on joints as well as on other organ systems
has greatly increased. In addition, maturation of existing electronic medical records, claims
datasets and registries enable us to better understand RA treatment patterns. Thus, the pro-
posal of an updated conceptual model that incorporates these understandings may be timely.
Table 2. Summary of pros and cons of proposed changes, expert input and agreement.
Changes proposed Pros and Cons Expert Inputs Expert
Agreement
Model Structure Pros: aligned with clinical practice & guidelines; allows
to captures patient subgroups, treatment heterogeneity,
non-joint outcomes;
Cons: increase in complexity; data availability
1. Ideal, however data may not be available to
populate model
2. Include cDMARD-naïve and cDMARD
inadequate responders
3. Changes may not materially impact ICER
4. The time involved in incorporating the changes
might not be worth the extra accuracy
3 of 5
Minimum of two disease activity
measures for treatment response
and disease progression
Pros: Aligns to treatment guidelines; less biased
estimates (vs. single measure)
Con: Data availability;
1. Data availability might be an issue 4 of 5
Disease activity based mapping of
utilities
Pros: Addresses the limitation of HAQ changes; Allows
the model to be based entirely on disease activity; could
lead to further improvements in mapping of utilities
Cons: Data availability
1. HAQ would still be an unbiased estimator of
disease progression
2. Reasons for HAQ was its association to cost in RA
3. Would not recommend RAPID3 by itself as it
based entirely on patient report. Good to see that
we are combining disease activity and RAPID3
3 of 5
Incorporation of subgroups Pros: Allows for specific and targeted HTA evaluations
Cons: No general agreement that the prognostic factors
are well established in RA; data availability
1. Double sero-positives are at a higher risk of
progressing (vs. single positive)
2. Patients who have erosive disease at baseline are
high risk of progression
3. Additional subgroups could include elderly i.e. age
>65 yrs (as they are increased risk of infections),
CV and other RA extra-articular manifestations
4. These are not just baseline factors
5 of 5
Real world treatment patterns: Pros: Allows for realistic estimates of cost and clinical
benefits of standard of care
Cons: data availability;
1. Generalizability of real world data vs. trials (where
efficacy was gained)
2. No controlled studies have examined switching
therapy in patients who are well controlled
3. GPs behavior cannot be clearly defined and
consistent for dose reduction
4 of 5
Incorporating extra-articular
manifestations of RA:
Pros: Allows for improved estimation of benefit and cost
of interventions
Cons: data availability;
1. CV and lung disease should be considered
2. Important if treatment would differentially impact
extra-articular manifestations
3. The strength of this evidence, particularly with
respect to changes in markers and changes in hard
outcomes is limited
5 of 5
Mortality Associated with RA Pros: allows for disease activity be the driver of benefits
Cons: potential for overestimation of survival; data
availability
No comments 5 of 5
Agreement in principal that these need to be evaluated in future economic models;
IR–inadequate response; ICER = Incremental cost effectiveness ratio
https://doi.org/10.1371/journal.pone.0205013.t002
Conceptual model for cost effectiveness analysis in RA
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In proposing the conceptual model we leveraged the earlier modeling approaches as certain
aspects are well established.
Overall, the proposed conceptual model reflects on 6 preselected areas of modelling cost-
effectiveness of drug treatment in moderate to severe RA in the 21th century. The major
changes that this conceptual model proposes are 1) use of at least two composite measures of
disease activity, with one used in sensitivity analyses, to evaluate both treatment response as
well as disease progression; 2) utility mapping based on disease activity 3) the consideration of
subgroups based on prognostic factors and potential treatment effect modifiers 4) the incorpo-
ration of realistic treatment patterns based on clinical practice/registry datasets 5) incorpo-
ration of non-joint related (extra-articular) outcomes and 6) mortality based on disease
activity.
Implementation of these structural changes could be prioritized based on the expected
impact on model estimates and on availability of data to populate the model. Incorporation of
subgroups based on prognostic factors ranked high on the prioritization order as this is rela-
tively straightforward. In addition, recent cost effectiveness analyses have demonstrated the
importance of incorporation of subgroups as these patients may have characteristics which are
potentially effect modifiers [29,30]. However, these analyses are still limited and further work
needs to be done to understand and define RA subgroups with combinations of prognostic
factors. Stratification of cost-effectiveness analysis by subgroups could have implication for
targeting specific therapies or combination of therapies to certain subgroups thereby improv-
ing the overall clinical outcomes and cost. This could pave the way for policies leading to per-
sonalized medicine in RA.
The second priority is deemed to be the use of a disease activity measure, to model treat-
ment response/stopping, disease progression, mapping of utility and mortality. The conceptual
model allows for at least two disease activity measures one as base case and one as sensitivity
analysis. Until an objective measure of disease activity is established in RA and used in routine
Fig 4. Updated conceptual model to evaluate cost effectiveness in RA.
https://doi.org/10.1371/journal.pone.0205013.g004
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clinical practice, impact of treatment on multiple disease activity measures will have to be eval-
uated in the same model/analysis. Though current mapping algorithms for utility use mixed
models based on HAQ, pain and disease activity. We believe further research is required com-
paring mapping algorithms using different disease activity measures. In addition, future
research should also evaluate the benefits of having direct measurement of utility from RA
clinical trials or from real world studies vs. mapping EQ-5D.
Next on the priority list is the incorporation of more realistic treatment algorithms into the
cost effectiveness model. Components of this proposed change such as glucocorticoids and
NSAID intensification, treatment discontinuation, dose escalation can be informed by current
RA registries, administrative claims and EMR database analysis. However, bDMARD dose de-
escalation is a new development based on a recent de-escalation trial design [37–40]. Current
evidence on real world dose de-escalation will be limited and hence the model will have to be
informed by clinical trial data at present. The last prioritized item is the incorporation of
extra-articular manifestation since more research is needed to develop RA-specific risk models
for both CV and pulmonary disease however, in the interim, treatment-specific risk reduction
of CV could be incorporated in sensitivity analysis.
The conceptual model presented in this manuscript concurs with some of the recommen-
dations of the consensus recommendations from the 2015 ‘Consensus Working Party’ such as
incorporation of AE based discontinuation, mapping of utility to disease activity [95]. How-
ever, there are also some major differences between the Consensus Working Party’s recom-
mendation and the current proposed conceptual model. The reliance by the Consensus
Working Party on DAS28 for treatment response could lead to biased estimates for therapies
such as anti-IL6 that have a disproportionate impact on acute phase reactants in DAS28. Addi-
tional differences include incorporation of detailed treatment patterns versus only treatment
discontinuation, specification of prognostic factors and incorporation of extra-articular
manifestations.
This analysis represent the first step in a model building exercise, the appropriate next step
would be to build a model prototype and evaluate the feasibility of operationalizing the pro-
posed changes. Limitations of the current approach is that the analysis informing the concep-
tual model was based on data from one US registry. Additional work based on other registries,
especially non-US registries, early RA registries and even registries focused on “treat to target”
approaches would be informative. Additional limitations, include the scope of the conceptual
model did not permit empirical evaluation of the proposed changes in reducing the current
uncertainty in economic models and the reliance on EQ-5D as measure of utility. Finally, we
did not evaluate the association between CDAI reduction and resource use/cost. However,
there is evidence that attainment of remission and LDA is associated with lower resource utili-
zation, higher quality of life and improved physical functioning [45].
Though we developed this conceptual model to meet payer/HTA needs, the focus has been
on payers using cost per QALY or cost per life year gained as a metric for decision-making.
Thus, our proposed model might not be applicable to address certain payer needs. For example
US payers are interested in shorter time horizon with outcomes such as remission. In addition,
treatment modules will have to be adapted to each country based on clinical practice data. Due
to our focus on HTA bodies that consider only direct cost in economic evaluations, our model
does not accommodate the indirect cost of RA into the analysis. Further work is required to
specifically address modeling of cost effectiveness from the societal perspective. Finally, it was
beyond the scope of this analysis to evaluate the impact of the availability of robust, compara-
tive, head-to-head clinical trials in reducing the short-term efficacy uncertainties in economic
evaluations of RA products.
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Despite these limitation the conceptual model presented in this manuscript is based on a
comprehensive approach that aims to incorporate both clinical and real-world evidence in the
economic evaluation of RA interventions. We believe that the proposed model framework can
potentially serve as a foundation for developing future cost effectiveness models in RA.
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